Cross-sectional Study to Establish the Point Prevalence of Serotype 19A Pneumococcal Nasopharyngeal Carriage of Fully Vaccinated Children Aged 13-48 Months Following Introduction of PCV13
Phase of Trial: Phase IV
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Sponsors Pfizer
- 06 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 04 Sep 2015 Accrual to date is 100% as per the United Kingdom Clinical Research Network record.
- 07 Aug 2015 Accrual to date is 94% as per United Kingdom Clinical Research Network record.